



Published in final edited form as:

Science. 2015 November 27; 350(6264): 1089–1092. doi:10.1126/science.aad3318.

## Malaria parasites target the hepatocyte receptor EphA2 for successful host infection

Alexis Kaushansky<sup>1,\*</sup>, Alyse N. Douglass<sup>1</sup>, Nadia Arang<sup>1</sup>, Vladimir Vigdorovich<sup>1</sup>, Nicholas Dambrauskas<sup>1</sup>, Heather S. Kain<sup>1</sup>, Laura S. Austin<sup>1,2</sup>, D. Noah Sather<sup>1</sup>, and Stefan H.I. Kappe<sup>1,2,\*</sup>

<sup>1</sup>Center for Infectious Disease Research, formerly Seattle Biomedical Research Institute, 307 Westlake Ave N, #500, Seattle, WA 98109, USA

<sup>2</sup>Department of Global Health, University of Washington, Seattle WA, USA

### Abstract

Invasion of a suitable host hepatocyte by mosquito-transmitted *Plasmodium* sporozoites is an essential early step in successful malaria parasite infection. Yet, precisely how sporozoites target their host cell and facilitate productive infection remains largely unknown. Here, we found that the hepatocyte EphA2 receptor was critical for establishing a permissive intracellular replication compartment, the parasitophorous vacuole. Sporozoites productively infected hepatocytes with high EphA2 expression and deletion of EphA2 protected mice from liver infection. Lack of host EphA2 phenocopied the lack of the sporozoite proteins P52 and P36. Our data suggests that P36 engages EphA2, which is likely to be a key step to establish the permissive replication compartment.

---

Malaria infections inflict a tremendous global health burden (1). Their causative agents, *Plasmodium* parasites, are transmitted to mammals as sporozoites by the bite of *Anopheles* mosquitoes. After entry into a capillary, sporozoites are carried to the liver where they pass through multiple cells before recognizing and invading hepatocytes. During invasion, the sporozoite forms a protective parasitophorous vacuole (PV) derived of hepatocyte plasma membrane, which ensconces the parasite, establishes the intrahepatocytic replication niche, and supports successful infection. It has been demonstrated that highly sulfated proteoglycans home sporozoites into the liver parenchyma (2, 3) and hepatocyte CD81 and scavenger receptor B1 are important for hepatocyte infection (4-6). Beyond this, the molecular mechanisms underlying infection remain poorly understood.

Hepatocytes exhibit differential susceptibility to infection. Sporozoites preferentially enter polyploid hepatocytes (7). Also, BALB/cByJ mice are more susceptible to *Plasmodium yoelii* sporozoite infection than BALB/cJ mice (8). To assess potential host receptors that might contribute to differential susceptibility, we used an antibody array to assess the levels of 28 activated receptors in the livers of BALB/cJ and BALB/cByJ mice. Nine receptors,

---

\*Correspondence to: Alexis Kaushansky, 307 Westlake Ave N. Suite 500, Seattle, WA, USA, 98109, alexis.kaushansky@cidresearch.org, 206-256-7216, fax: 206-256-7229 or Stefan H.I. Kappe, 307 Westlake Ave N. Suite 500, Seattle, WA, USA, 98109, stefan.kappe@cidresearch.org, 206-256-7205, fax: 206-256-7229.

including EphA2, were present in significantly ( $P < 0.01$ ) and substantially elevated levels in highly susceptible BALB/cByJ mice (Table S1). Polyploid hepatocytes expressed higher levels of EphA2 (Fig. S1).

In metazoans, Eph receptors and their cognate Ephrin ligands mediate cell-cell contact (9), making EphA2 a candidate to mediate hepatocyte-sporozoite interaction. Furthermore, an Ephrin-like fold is present in the parasite 6-Cys protein family (10). Although Hepa1-6 cells held consistent EphA2 expression across passages, variation within a culture was substantial (Fig. S2) and we thus postulated that if EphA2 mediates sporozoite invasion, there might be variable susceptibilities within a culture of Hepa1-6 cells. When we infected Hepa1-6 cells with *P. yoelii* sporozoites, we observed parasites in hepatocytes that expressed high levels of EphA2 after 24h (Fig. 1A). This was also observed 1.5h after infection by flow cytometry (Fig. 1B, Fig. S3A), as parasite-infected cells exhibited significantly increased levels of both total (Fig. 1C) and surface (Fig. S3B-D) EphA2. Similarly, the frequency of infection in the top 50% of EphA2-expressing cells (EphA2<sup>high</sup>) was elevated compared to infection in cells with the lowest 50% of EphA2 levels (EphA2<sup>low</sup>) (Fig. 1D). When we included only the top 40%, 30% or 20% or 10% of EphA2 expressing cells in the EphA2<sup>high</sup> gate, the preference was even more dramatic (Fig. S3E). We next challenged BALB/c mice with  $10^6$  *P. yoelii* sporozoites and isolated hepatocytes after 3 h. We again observed a strong parasite preference for EphA2<sup>high</sup> hepatocytes (Fig. 1E, F, G). Finally, we asked if the preference for infection of EphA2<sup>high</sup> hepatocytes was conserved in the human parasites by infecting HC-04 hepatocytes with *Plasmodium falciparum*. We observed elevated levels of EphA2 in infected cells and a higher proportion of sporozoite-containing cells in the EphA2<sup>high</sup> population (Fig. 1H-J).

EphA2 has an extracellular ligand-binding region and an intracellular kinase domain, which mediates downstream signaling. To assess if interaction with the extracellular portion of EphA2 is critical for *Plasmodium* infection, we infected hepatocytes in the presence of an antibody that binds extracellular EphA2. This reduced sporozoite infection in a dose-dependent manner (Fig. 1K). In contrast, inhibiting the kinase domain of EphA2 did not inhibit infection (Fig. S4). Thus, the extracellular portion of EphA2 facilitates *Plasmodium* invasion of hepatocytes.

To ask if EphA2 levels were important for liver stage parasite survival and development, we measured infection rates in EphA2<sup>high</sup> and EphA2<sup>low</sup> cells over the course of 48 h, normalizing each infection rate to the rate at 1.5h post-infection. While EphA2<sup>high</sup>-infected cells were maintained throughout the course of infection, the number of EphA2<sup>low</sup>-infected cells decreased over time (Fig. 2A). This could not be accounted for by division rates as we observed lower levels of host cell division among EphA2<sup>low</sup> cells, suggesting actual underestimation of the impact of EphA2 on infected cell survival (Fig. S5). When we infected EphA2<sup>(-/-)</sup> mice or wild-type mice with  $10^5$  *P. yoelii* sporozoites, we observed a dramatic decrease in liver stage burden after 42 h in EphA2<sup>(-/-)</sup> mice (Fig. 2B), which caused a delay in the onset of blood stage infection by 1-3 days (Fig. 2C). Thus, without EphA2, the host is far less susceptible to productive parasite liver infection.

The PV membrane (PVM) is critical for liver stage development. One liver stage PVM resident protein, UIS4, is highly expressed after invasion when it is exported to the PVM (11), making it a useful marker. We constructed a *P. yoelii* parasite line, which expressed a UIS4-Myc fusion protein driven by the endogenous UIS4 promoter (Fig. 2D). This allowed us to monitor PVM prevalence in infected cells by flow cytometry (UIS4<sup>POS</sup>). Most of the UIS4<sup>POS</sup> - infected host cells were EphA2<sup>high</sup> (Fig. 2E). Similarly, the level of EphA2 expression was higher in UIS4<sup>POS</sup>-infected cells than in UIS4<sup>neg</sup>-infected cells (Fig. 2F). Thus, sporozoites not only preferentially entered EphA2<sup>high</sup> cells, but invasion with PVM formation was far more effective in these cells. UIS4<sup>neg</sup>-infected hepatocytes suffered a higher frequency of cell death (Fig. 2G).

Two members of the parasite protein 6-Cys family, P52 and P36, are expressed in sporozoites and are important for invasion of hepatocytes (15-17) with PVM formation (15). In mouse livers, parasites without P52 or P36 are almost entirely eliminated within 3 h (Fig. S6). We asked if lack of P52 and P36 phenocopies the lack of host EphA2 and found that *p52*<sup>-</sup>/*p36*<sup>-</sup> *P. yoelii* sporozoites exhibited a reduced preference for EphA2<sup>high</sup> cells (Fig. 3A).

The 6-Cys protein P12 shows structural similarity to the mammalian ligand for EphA2, EphrinA1, while sharing no amino acid sequence similarity (10). We showed that an interaction in the extracellular region of EphA2 was required for sporozoite entry using an EphA2 blocking antibody (Fig. 1K). Therefore, we asked if the presence of P36 and P52 was required for the antibody to block sporozoite entry. While the EphA2 antibody blocked infection with wild-type *P. yoelii* sporozoites, *p52*<sup>-</sup>/*p36*<sup>-</sup> sporozoite entry was not impacted (Fig. 3B). These data suggest that P36 or P52 directly engage EphA2 at the point of host cell invasion. We next tested if P52 or P36 could directly impede the interaction between EphrinA1 and EphA2 on the hepatocyte surface, which results in EphA2 activation. When we added EphrinA1 in the presence of P36 to Hepa1-6 cells, P36 blocked activation of EphA2 (Fig. 3C, D). P52 however, did not block EphrinA1-mediated activation of EphA2 (Fig. 3C, D). To assess if the interaction between EphA2 and P36 is conserved in human parasites, we assessed levels of EphA2 in *P. falciparum* wild-type or P52/P36 deficient parasite-infected HC04 cells. The *Pf* P52/P36-deficient sporozoites partially lost selectivity for EphA2<sup>high</sup> HC04 cells when compared to *Pf* wild-type sporozoites. Thus, P36 engages EphA2, but does not trigger its activation in rodent and human parasites.

We have shown that both host EphA2 and parasite 6-Cys proteins have a role in invasion and establishment of the growth-permissive intracellular niche during sporozoite infection of hepatocytes. Without either component, the parasite can still enter hepatocytes, but does so without a PVM, which can lead to death of the infected hepatocyte. The convergence of infection-permissive phenotypes is best explained by an interaction between parasite P36 and hepatocyte EphA2 at the point of sporozoite invasion when the PVM is formed. This role for EphA2 in hepatocyte infection does not preclude additional critical hepatocyte receptors for infection. Interventional strategies aimed at either EphA2 or sporozoite 6-Cys proteins might block parasite infection before the onset of clinical malaria.

## Supplementary Material


Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We are grateful to W. Betz for mosquito and sporozoite production. We thank the Center for Infectious Disease Research vivarium staff for their work with mice. This work was funded by an R01 to SHIK and AK (1R01GM101183-01A1). AK is also a recipient of a Transition to Independence Award (1K99AI111785-01A1) which partially funded this work. AK, NA, AND, VV, ND, HK and LSA performed experiments. AK, DNS and SHIK supervised the research. AK and SHIK wrote the paper.

## References and Notes

1. Kappe SH, Vaughan AM, Boddey JA, Cowman AF. *Science*. 2010; 328:862–866. [PubMed: 20466924]
2. Coppi A, et al. *Cell host & microbe*. 2007; 2:316–327. [PubMed: 18005753]
3. Frevert U, et al. *The Journal of experimental medicine*. 1993; 177:1287–1298. [PubMed: 8478608]
4. Silvie O, et al. *Nature medicine*. 2003; 9:93–96.
5. Yaloui S, et al. *Cell host & microbe*. 2008; 4:283–292. [PubMed: 18779054]
6. Rodrigues CD, et al. *Cell host & microbe*. 2008; 4:271–282. [PubMed: 18779053]
7. Austin LS, Kaushansky A, Kappe SH. *Cellular microbiology*. 2014; 16:784–795. [PubMed: 24612025]
8. Kaushansky A, et al. *Infection and immunity*. 2014
9. Lisabeth EM, Falivelli G, Pasquale EB. *Cold Spring Harbor perspectives in biology*. 2013; 5
10. Arredondo SA, et al. *Proc Natl Acad Sci U S A*. 2012; 109:6692–6697. [PubMed: 22493233]
11. Mueller AK, et al. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:3022–3027. [PubMed: 15699336]
12. Kaiser K, Camargo N, Kappe SH. *The Journal of experimental medicine*. 2003; 197:1045–1050. [PubMed: 12707302]
13. Annoura T, et al. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology*. 2014; 28:2158–2170. [PubMed: 24509910]
14. van Dijk MR, et al. *PLoS pathogens*. 2010; 6:e1000853. [PubMed: 20386715]
15. Labaied M, et al. *Infection and immunity*. 2007; 75:3758–3768. [PubMed: 17517871]
16. van Dijk MR, et al. *Proc Natl Acad Sci U S A*. 2005; 102:12194–12199. [PubMed: 16103357]
17. VanBuskirk KM, et al. *Proc Natl Acad Sci U S A*. 2009; 106:13004–13009. [PubMed: 19625622]



**Fig. 1.** *Plasmodium* sporozoites invade hepatocytes with high EphA2 expression. (A) Hepa1-6 cells were infected with *P. yoelii* sporozoites and visualized by immunofluorescence 24 h post infection. Scale bar is 5  $\mu$ M. (B, C, D) Hepa1-6 cells were infected with  $10^5$  *P. yoelii* sporozoites. (B) Distribution of EphA2 1.5h after infection. (C) EphA2 levels were compared between parasite-infected and uninfected cells. (D) Parasite-infection rates within the highest and lowest 50% fraction of EphA2-expressing cells (designated EphA2<sup>high</sup> and EphA2<sup>low</sup>). The percentages represent the proportion of infected cells within each subset. (E, F, G) BALB/c mice were infected with  $10^6$  *P. yoelii* sporozoites by i.v. injection.


Analysis of hepatocytes performed as in B-D. **(H, I, J)** HC04 cells were infected with  $10^5$  *P. falciparum* sporozoites. Analysis performed as in B-D. **(K)** Hepa1-6 cells were incubated with  $\alpha$ EphA2 or IgG control 30 min before infection with  $10^5$  *P. yoelii* sporozoites. Infection rate was normalized to the rate with IgG. All data represent three independent experiments.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript

**Fig. 2.**

EphA2 impacts PVM formation. **(A)** Time course showing maintenance of *P. yoelii* infection in Hepa1-6 cells. Maintenance of infection was defined as the infection rate at a given point divided by the infection rate at 1.5 h post-infection. **(B)** EphA2<sup>-/-</sup> or age-matched wild-type mice were infected with 10<sup>5</sup> *P. yoelii* sporozoites. Infection was assessed 42 h post-infection by qPCR. Error bars show SEM. **(C)** EphA2<sup>-/-</sup> or strain-matched wild-type mice were infected with 10<sup>2</sup> *P. yoelii* sporozoites. Patency was monitored daily by thin smear. **(D)** *PyUIS-Myc* parasite in Hepa1-6 cells 24 h post-infection. Scale bar is 5 μM. **(E, F)** *PyUIS-Myc* parasites were used to infect Hepa1-6 cells and analyzed for the presence of *PyUIS-Myc* after 24 h. **(G)** *PyUIS4-Myc*-infected Hepa1-6 cells were assessed for permeability after 48 h. All data represent three independent experiments.



**Fig. 3.**

P36 interacts with EphA2. (A)  $2 \times 10^5$  WT or p52<sup>-</sup>/p36<sup>-</sup> *P. yoelii* parasites were used to infect Hepa 1-6 cells. Levels of EphA2 were monitored in infected and uninfected cells. (B) *P. yoelii* sporozoites were used to infect Hepa 1-6 cells after 30 min treatment with IgG or  $\alpha$ -EphA2 antibody. Infection levels were normalized to infection rate in the presence of IgG. (C, D) Hepa1-6 cells were incubated with recombinant P52 or P36 alone or in combination with 10 minutes of EphrinA1 treatment. Western blot shows levels of pEphA2 (pY772). (E)  $2 \times 10^5$  WT or p52<sup>-</sup>/p36<sup>-</sup>/sap1<sup>-</sup> *P. falciparum* sporozoites were used to infect  $6 \times 10^5$  HC04 cells. EphA2 levels were measured in infected and uninfected cells. All data represent three independent experiments.